| Market Capitalization (Millions $) |
260 |
| Shares
Outstanding (Millions) |
68 |
| Employees |
113 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-302 |
| Cash Flow (TTM) (Millions $) |
-92 |
| Capital Exp. (TTM) (Millions $) |
36 |
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a biopharmaceutical company that is dedicated to saving lives and improving the quality of life for people who suffer from neurodegenerative diseases. The company was founded in 2013 by a group of renowned clinicians, scientists, and entrepreneurs who were keen on addressing the severe unmet needs of patients who were suffering from diseases such as ALS, Alzheimer's, and Parkinson's.
Amylyx Pharmaceuticals is headquartered in Cambridge, Massachusetts, and it has a strong reputation as a leader in the development of treatments for neurodegenerative diseases. The company's research and development team is composed of some of the industry's most innovative and experienced scientists who have developed some of the most successful treatments for these diseases.
One of the most notable aspects of Amylyx Pharmaceuticals' approach is its focus on finding therapies that aim to treat the underlying cause of the disease rather than just the symptoms. The company's flagship product is AMX0035, which is developed as a combination of two small molecules that aim to protect and restore key cellular processes in the central nervous system.
Amylyx Pharmaceuticals has received numerous accolades for its groundbreaking work in neurodegenerative diseases. The company has been recognized by prestigious organizations such as the National Institutes of Health, the ALS Association, and the Alzheimer's Association. Amylyx Pharmaceuticals has also raised millions in funding from investors such as Morningside Ventures and the ALS Investment Fund.
The company's approach to research and development has also garnered praise from the scientific community. Amylyx Pharmaceuticals has published numerous peer-reviewed papers in top-tier journals that showcase the company's innovative approach to developing therapies for neurodegenerative diseases.
Overall, Amylyx Pharmaceuticals Inc. is a forward-thinking and innovative biopharmaceutical company that is dedicated to improving the lives of individuals afflicted with neurodegenerative diseases. With a strong focus on research and development, the company is poised to continue its exceptional progress in developing groundbreaking treatments for these devastating illnesses.
Company Address: 43 Thorndike St. Cambridge 2141 MA
Company Phone Number: 682-0917 Stock Exchange / Ticker: NASDAQ AMLX
|
